ramucirumab

Ramucirumab (IMC-1121B, trade name Cyramza) is directed against the vascular endothelial growth factor receptor 2 (VEGFR2).

By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.

It is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Clinical trials

 mammary adenocarcinoma (breast cancer)
 hepatocellular carcinoma (HCC)
 urothelial carcinoma